Researchers examined data from 82,000 TAVR patients, focusing on echocardiography-defined PPM. They shared their results in JACC: Cardiovascular Imaging.

Read our review of some of the biggest FDA-related stories that have hit cardiology in the last month, including news from Viz.ai, Edwards Lifesciences, Abiomed and Medtronic. 

This is the fourth device in Medtronic's Evolut TAVR platform. The self-expanding valve gained FDA approval in 2021 for the treatment of high- and low-risk patients presenting with symptomatic severe aortic stenosis.

The conventional transfemoral approach is not always possible during TAVR procedures, leaving care teams with an important decision to make. 

Diabetes and atrial fibrillation are just some of the factors that can increase a patient's risk of being hospitalized for heart failure within one year of undergoing a successful TAVR procedure.

New research in JACC: Cardiovascular Interventions suggests improved collaborations between cardiologists and neurologists could help TAVR patients live longer after a periprocedural stroke. 

The connection between cognitive impairment and postoperative delirium among TAVR patients stood out as a definite concern to the study's authors.

If researchers can find ways to prevent AKI after TAVR, it could help decrease the risk of poor outcomes in more ways than one.